

BIBLIOGRAFIA

- [1] Kyle RA. ***Multiple myeloma: how did it begin?*** Mayo Clin Proc. 1994 Jul;69(7):680-3. PMID: 8015334
- [2] Saunders G. ***Overview of drug therapy for multiple myeloma.*** J Oncol Pharm Pract. 2005 Sep;11(3):83-100. PMID: 16390597
- [3] Sirohi B, Powels R. ***Multiple Myeloma.*** Lancet. 2004 Mar 13;363(9412):875-87. Review. PMID: 15031034
- [4] Kuehl WM, Bergsagel PL. ***Multiple myeloma: evolving genetic events and host interactions.*** Nat Rev Cancer. 2002 Mar;2(3):175-87. Review. PMID: 11990854
- [5] Ahmann GJ, Jalal SM, Juneau AL *et al.* ***A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies.*** Cancer Genet Cytogenet. 1998 Feb;101(1):7-11. PMID: 9460493
- [6] Avet-Loiseau H, Facon T, Grosbois B *et al.*; Intergroupe Francophone du Myelome. ***Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation.*** Blood. 2002 Mar 15;99(6):2185-91. PMID: 11877296

- [7] Sonneveld P, Segeren CM. **Changing concepts in multiple myeloma: from conventional chemotherapy to high-dose treatment.** Eur J Cancer. 2003 Jan;39(1):9-18. Review. PMID: 12504653
- [8] Bruno B, Rotta M, Giaccone L, et al. **New drugs for treatment of multiple myeloma.** Lancet Oncol. 2004 Jul;5(7):430-42. Review. PMID: 15231250
- [9] Rajkumar SV, Kyle RA. **Multiple myeloma: diagnosis and treatment.** Mayo Clin Proc. 2005 Oct;80(10):1371-82. Review. PMID: 16212152
- [10] Gado K, Gopcsa L, Paloczi K, Domjan G. **Therapy of multiple myeloma.** Magy Onkol. 2001;45(1):23-30. PMID: 12050724
- [11] Myeloma Trialists' Collaborative Group (MTC Group). **Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials.** J Clin Oncol. 1998 Dec;16(12):3832-42. PMID: 9850028

- [12] Lokhorst HM, Meuwissen OJ, Bast EJ, Dekker AW. **VAD chemotherapy for refractory multiple myeloma.** Br J Haematol. 1989 Jan;71(1):25-30. PMID: 2644970
- [13] Alexanian R, Barlogie B, Tucker S. **VAD-based regimens as primary treatment for multiple myeloma.** Am J Hematol. 1990 Feb;33(2):86-9. PMID: 2301376
- [14] NJEM 1996; 335:91-91
- [15] Barlogie B, Jagannath S, Vesole DH, et al. **Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.** Blood. 1997 Feb 1;89(3):789-93. PMID: 9028309
- [16] Reiffers J, Marit G, Boiron JM. **Autologous blood stem cell transplantation in high-risk multiple myeloma.** Br J Haematol. 1989 Jun;72(2):296-7. PMID: 2569326
- [17] Femand JP, Chevret S, Ravaud P, et al. **High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients.** Blood. 1993 Oct 1;82(7):2005-9. PMID: 8104534

- [18] Demuyneck H, Delforge M, Verhoef G, *et al.* **Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF or rhG-CSF.** Br J Haematol. 1995 Jun;90(2):384-92. PMID: 7540856
- [19] Knudsen LM, Rasmussen T, Jensen L, Johnsen HE. **Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment.** Med Oncol. 1999 Dec;16(4):245-54. PMID: 10618687
- [20] McElwain TJ, Powles RL. **High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.** Lancet. 1983 Oct 8;2(8354):822-4. PMID: 6137651
- [21] Harousseau JL, Milpied N, Laporte JP, *et al.* **Double-intensive therapy in high-risk multiple myeloma.** Blood. 1992 Jun 1;79(11):2827-33. PMID: 1350228
- [22] Barlogie B, Alexanian R, Smallwood L, *et al.* **Prognostic factors with high-dose melphalan for refractory multiple myeloma.** Blood. 1988 Dec;72(6):2015-9. PMID: 3196876

- [23] Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. **High-dose melphalan with autologous bone marrow transplantation for multiple myeloma.** *Blood.* 1986 May;67(5):1298-301. PMID: 3516252
- [24] Barlogie B, Jagannath S, Tricot G, et al. **Advances in the treatment of multiple myeloma.** *Adv Intern Med.* 1998;43:279-320. Review. PMID: 9506186
- [25] Moreau P, Facon T, Attal M, et al; Intergroupe Francophone du Myelome. **Comparison of 200 mg/m² melphalan and 8 Gy total body irradiation plus 140 mg/m² melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial.** *Blood.* 2002 Feb 1;99(3):731-5. PMID: 11806971
- [26] Dicato M, Boccadoro M, Cavenagh J, et al. **Management of multiple myeloma with bortezomib: experts review the data and debate the issues.** *Oncology.* 2006;70(6):474-82. Epub 2007 Feb 2. Review. PMID: 17283449
- [27] Palumbo A, Giaccone L, Bertola A, et al. **Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma.** *Haematologica.* 2001 Apr;86(4):399-403. PMID: 11325646

- [28] Garcia-Sanz R, Gonzalez-Fraile MI, Sierra M, et al. **The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma.** Hematol J. 2002;3(1):43-8. PMID: 11960395
- [29] Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K. **New drugs for myeloma.** Oncologist. 2007 Jun;12(6):664-89. Review. PMID: 17602058
- [30] Thomas S, Alexanian R. **Current treatment strategies for multiple myeloma.** Clin Lymphoma Myeloma. 2007 Apr;7 Suppl 4:S139-44. Review. PMID: 17562251
- [31] Moro S, Beretta GL, Dal Ben D, Nitiss J, Palumbo M, Capranico G. **Interaction model for anthracycline activity against DNA topoisomerase II.** Biochemistry. 2004 Jun 15;43(23):7503-13. PMID: 15182192
- [32] Zhou Q, Chowbay B. **Determination of doxorubicin and its metabolites in rat serum and bile by LC: application to preclinical pharmacokinetic studies.** J Pharm Biomed Anal. 2002 Nov 7;30(4):1063-74. PMID: 12408897

- [33] Meneghini R. **Genotoxicity of active oxygen species in mammalian cells.** Mutat Res. 1988 May;195(3):215-30. Review. PMID: 3283541
- [34] Ferguson LR, Pearson AE. **The clinical use of mutagenic anticancer drugs.** Mutat Res. 1996 Aug 17;355(1-2):1-12. PMID: 8781574
- [35] Chabner BA, Horwitz SB. **Plant alkaloids.** Cancer Chemother Biol Response Modif. 1990;11:74-81. Review. PMID: 1977436
- [36] Junping W, Takayama K, Nagai T, Maitani Y. **Pharmacokinetics and antitumor effects of vincristine carried by microemulsions composed of PEG-lipid, oleic acid, vitamin E and cholesterol.** Int J Pharm. 2003 Jan 30;251(1-2):13-21. PMID: 12527171
- [37] Pass GJ, Carrie D, Boylan M, et al. **Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse.** Cancer Res. 2005 May 15;65(10):4211-7. PMID: 15899812
- [38] Gerlach JH, Kartner N, Bell DR, Ling V. **Multidrug resistance.** Cancer Surv. 1986;5(1):25-46. Review. PMID: 2885085

- [39] Kartner N, Riordan JR, Ling V. **Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines.** Science. 1983 Sep 23;221(4617):1285-8. PMID: 6137059
- [40] Ling V, Kartner N, Sudo T, Siminovitch L, Riordan JR. **Multidrug-resistance phenotype in Chinese hamster ovary cells.** Cancer Treat Rep. 1983 Oct;67(10):869-74. Review. PMID: 6354434
- [41] Bourhis J, Riou G, Benard J. **Expression of P-glycoprotein 170 (GP 170) and drug resistance in human cancers.** Bull Cancer. 1990;77(10):957-65. Review. PMID: 1979014
- [42] Bodor M, Kelly EJ, Ho RJ. **Characterization of the human MDR1 gene.** AAPS J. 2005 Feb 16;7(1):E1-5. PMID: 16146331
- [43] Sakaeda T. **MDR1 genotype-related pharmacokinetics: fact or fiction?** Drug Metab Pharmacokinet. 2005 Dec;20(6):391-414. Review. PMID: 16415525
- [44] Loo TW, Clarke DM. **Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux.** J Membr Biol. 2005 Aug;206(3):173-85. Review. PMID: 16456713

- [45] Juliano RL, Ling V. **A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.** Biochim Biophys Acta. 1976 Nov 11;455(1):152-62. PMID: 990323
- [46] Ambudkar SV, Kim IW, Sauna ZE. **The power of the pump: mechanisms of action of P-glycoprotein (ABCB1).** Eur J Pharm Sci. 2006 Apr;27(5):392-400. Epub 2005 Dec 13. Review. PMID: 16352426
- [47] Rosenberg MF, Velarde G, Ford RC, et al. **Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle.** EMBO J. 2001 Oct 15;20(20):5615-25. PMID: 11598005
- [48] Rosenberg MF, Kamis AB, Callaghan R, Higgins CF, Ford RC. **Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding.** J Biol Chem. 2003 Mar 7;278(10):8294-9. PMID: 12501241
- [49] Rosenberg MF, Callaghan R, Modok S, Higgins CF, Ford RC. **Three-dimensional structure of P-glycoprotein: the transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state.** J Biol Chem. 2005 Jan 28;280(4):2857-62. PMID: 15485807

- [50] Shapiro AB, Ling V. ***The mechanism of ATP-dependent multidrug transport by P-glycoprotein.*** Acta Physiol Scand Suppl. 1998 Aug;643:227-34. Review. PMID: 9789565
- [51] Relling MV. ***Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs?*** Ther Drug Monit. 1996 Aug;18(4):350-6. PMID: 8857549
- [52] Ueda K, Okamura N, Hirai M, et al. ***Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone.*** J Biol Chem. 1992 Dec 5;267(34):24248-52. PMID: 1360010
- [53] Marzolini C, Paus E, Buclin T, Kim RB. ***Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance.*** Clin Pharmacol Ther. 2004 Jan;75(1):13-33. Review. PMID: 14749689
- [54] Kioka N, Tsubota J, Kakehi Y, et al. ***P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance.*** Biochem Biophys Res Commun. 1989 Jul 14;162(1):224-31. PMID: 2568832
- [55] Mickley LA, Lee JS, Weng Z, et al. ***Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells,***

unselected and drug-selected cell lines, and human tumors.

Blood. 1998 Mar 1;91(5):1749-56. PMID: 9473242

- [56] Hoffmeyer S, Burk O, von Richter O, et al. ***Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.*** Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8. PMID: 10716719
- [57] Cascorbi I, Gerloff T, John A, et al. ***Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects.*** Clin Pharmacol Ther. 2001 Mar;69(3):169-74. PMID: 11240981
- [58] Hitzl M, Drescher S, van der Kuip H, et al. ***The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells.*** Pharmacogenetics. 2001 Jun;11(4):293-8. PMID: 11434506
- [59] Fellay J, Marzolini C, Meaden ER, et al; Swiss HIV Cohort Study. ***Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.*** Lancet. 2002 Jan 5;359(9300):30-6. PMID: 11809184

- [60] Nakamura T, Sakaeda T, Horinouchi M, et al. ***Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects.*** Clin Pharmacol Ther. 2002 Apr;71(4):297-303. PMID: 11956513
- [61] Illmer T, Schuler US, Thiede C, et al. ***MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients.*** Cancer Res. 2002 Sep 1;62(17):4955-62. PMID: 12208746
- [62] Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. ***Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability.*** Pharmacogenet Genomics. 2005 Oct;15(10):693-704. PMID: 16141795
- [63] Wang D, Sadee W. ***Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1).*** AAPS J. 2006 Aug 18;8(3):E515-20. Review. PMID: 17025270
- [64] Kimchi-Sarfaty C, Oh JM, Kim IW, et al. ***A "silent" polymorphism in the MDR1 gene changes substrate specificity.*** Science. 2007 Jan 26;315(5811):525-8. PMID: 17185560
- [65] Schaefer M, Roots I, Gerloff T. ***In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and***

- ALA893THR polymorphisms.** Pharmacogenet Genomics. 2006 Dec;16(12):855-61. PMID: 17108809
- [66] Horinouchi M, Sakaeda T, Nakamura T, et al. **Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin.** Pharm Res. 2002 Oct;19(10):1581-5. PMID: 12425480
- [67] Tang K, Ngoi SM, Gwee PC, et al. **Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations.** Pharmacogenetics. 2002 Aug;12(6):437-50. PMID: 12172212
- [68] Tang K, Wong LP, Lee EJ, Chong SS, Lee CG. **Genomic evidence for recent positive selection at the human MDR1 gene locus.** Hum Mol Genet. 2004 Apr 15;13(8):783-97. PMID: 14976162
- [69] Dean M, Rzhetsky A, Allikmets R. **The human ATP-binding cassette (ABC) transporter superfamily.** Genome Res. 2001 Jul;11(7):1156-66. Review. PMID: 11435397
- [70] Dean M, Annilo T. **Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates.** Annu Rev Genomics Hum Genet. 2005;6:123-42. Review. PMID: 16124856

- [71] Ameyaw MM, Regateiro F, Li T, et al. ***MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity.*** Pharmacogenetics. 2001 Apr;11(3):217-21. PMID: 11337937
- [72] Komoto C, Nakamura T, Sakaeda T, et al. ***MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer.*** Drug Metab Pharmacokinet. 2006 Apr;21(2):126-32. PMID: 16702732
- [73] Sonneveld P. ***Multidrug resistance in haematological malignancies.*** J Intern Med. 2000 May;247(5):521-34. Review. PMID: 10809991
- [74] Schaich M, Soucek S, Thiede C, Ehninger G, Illmer T; SHG AML96 Study Group. ***MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia.*** Br J Haematol. 2005 Feb;128(3):324-32. PMID: 15667534
- [75] Casale F, D'Angelo V, Addeo R, et al. ***P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia.*** Oncol Rep. 2004 Dec;12(6):1201-7. PMID: 15547738

- [76] Schwarzenbach H. **Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma.** Med Oncol. 2002;19(2):87-104. PMID: 12180485
- [77] Schilthuisen C, Broyl A, van der Holt B, de Knecht Y, Lokhorst H, Sonneveld P. **Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma.** Haematologica. 2007 Feb;92(2):277-8. PMID: 17296590
- [78] Wang D, Ke XY, Wang J, Xu F, Hu YF. **Correlation between MDR1 genetic polymorphism and prognosis in acute myeloid leukemia.** Zhonghua Yi Xue Za Zhi. 2007 May 29;87(20):1384-8. PMID: 17785057
- [79] Kim DH, Park JY, Sohn SK, et al. **Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia.** Int J Cancer. 2006 May 1;118(9):2195-201. PMID: 16331627
- [80] EBMT: www.ebmt.org
- [81] van der Holt B, Van den Heuvel-Eibrink MM, Van Schaik RH, et al. **ABCB1 gene polymorphisms are not associated with treatment**

outcome in elderly acute myeloid leukemia patients. Clin Pharmacol Ther. 2006 Nov;80(5):427-39. PMID: 17112800

[82] Jamroziak K, Robak T. **Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies.** Hematology. 2004 Apr;9(2):91-105. Review. PMID: 15203864

[83] Gollapud S, Gupta S. **Anti-P-glycoprotein antibody-induced apoptosis of activated peripheral blood lymphocytes: a possible role of P-glycoprotein in lymphocyte survival.** J Clin Immunol. 2001 Nov;21(6):420-30. PMID: 11811787

[84] Pawlik A, Baskiewicz-Masiuk M, Machalinski B, Kurzawski M, Gawronska-Szklarz B. **Involvement of C3435T and G2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone.** Eur J Pharmacol. 2005 Dec 28;528(1-3):27-36. PMID: 16321374

[85] Johnstone RW, Ruefli AA, Smyth MJ. **Multiple physiological functions for multidrug transporter P-glycoprotein?** Trends Biochem Sci. 2000 Jan;25(1):1-6. Review. PMID: 10637601

[86] Buda G, Maggini V, Galimberti S, Martino A, Giuliani N, Morabito F, Genestreti G, Iacopino P, Rizzoli V, Barale R, Rossi AM, Petrini M. ***MDR1 polymorphism influences the outcome of multiple myeloma*** patients. Br J Haematol. 2007 Jun;137(5):454-6. PMID: 17488488

[87] Cavo M, Tosi P, Zamagni et . Prospective, ***randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.*** J Clin Oncol. 2007 Jun 10;25(17):2434-41. PMID: 17485707